Business Standard

CCI clears Berhyanda's 76% stake acquisition in Suven Pharmaceuticals

Berhyanda Ltd is a wholly-owned subsidiary of Berhyanda Midco Ltd, which is an affiliate of Advent International Corporation

Govt plans major amendments to Competition Act, may curtail CCI's powers

Competition Commission

Press Trust of India New Delhi

Listen to This Article

The Competition Commission of India (CCI) on Thursday said it has cleared Berhyanda Ltd's acquisition of a 76.10 per cent stake in pharmaceutical firm Suven Pharmaceuticals Ltd.
Berhyanda Ltd is a wholly-owned subsidiary of Berhyanda Midco Ltd, which is an affiliate of Advent International Corporation.
The proposed combination relates to the acquisition by Berhyanda Ltd for up to 76.10 per cent of the voting share capital of Suven Pharmaceuticals Ltd, by way of a share purchase agreement dated December 26, 2022, and pursuant to the mandatory open offer in compliance with Sebi's SAST (Substantial Acquisition of Shares and Takeovers) regulations, according to an official release.
Suven Pharmaceuticals Ltd is a biopharmaceutical company that offers its services to global pharmaceutical and agrochemical majors.
Deals beyond a certain threshold require approval from the regulator, which keeps a tab on unfair business practices in the marketplace.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Apr 20 2023 | 9:32 PM IST

Explore News